Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2026-01-05 @ 8:27 PM
Study NCT ID:
NCT02951156
Status:
TERMINATED
Last Update Posted:
2020-12-17
First Post:
2016-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-12-16
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-12-02
Completion Date Type:
ACTUAL
First Submit Date:
2016-10-19
First Submit QC Date:
None
Study First Post Date:
2016-11-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-11-20
Results First Submit QC Date:
None
Results First Post Date:
2020-12-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-20
Last Update Post Date:
2020-12-17
Last Update Post Date Type:
ACTUAL